Every Form 4 that ALX Oncology Holdings Inc. (ALXO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALXO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALXO filings page.
ALX ONCOLOGY HOLDINGS INC (ALXO) director and chief executive officer Jason Lettmann reported a sale of 2,230 shares of Common Stock on August 17, 2026 at $1.93 per share. The shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Following this transaction, he directly owned 294,379 shares, which includes 3,000 shares acquired under the issuer's employee stock purchase plan on June 30, 2026.
ALX Oncology Holdings Inc. (ALXO) reported that officer Shelly Wong, SVP, Finance and CAO, sold 573 shares of Common Stock on 2026-08-17 at $1.93 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from the vesting of restricted stock units. After this transaction, Wong directly holds 87,828 shares of ALXO common stock.
ALX Oncology Holdings SVP Shelly Wong reported an open-market sale of 1,404 shares of Common Stock at a weighted average price of $2.04 per share. According to the filing, the shares were sold to satisfy her tax obligations related to vesting of restricted stock units.
After this transaction, she directly holds 88,401 shares, which includes 3,000 shares acquired under the company’s employee stock purchase plan on June 30, 2026.
ALX Oncology Holdings Inc. reported that Chief Development & Operating Officer Jeff E. Knight received a grant of stock options covering 800,000 shares of Common Stock. The options have an exercise price of $1.68 per share and expire on April 15, 2036.
According to the vesting terms, one-fourth of the options vest on April 13, 2027 and the remaining options vest in equal monthly installments over the following three years. After this grant, Knight holds 800,000 stock options directly.
ALX Oncology Holdings Inc reported that Chief Medical Officer Barbara Klencke received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $1.68 per share and expire on April 15, 2036.
One-fourth of the option shares vest on February 25, 2027, and the remaining shares vest in equal monthly installments of 1/48th thereafter. This is a compensation-related award rather than an open-market stock purchase or sale.
ALX Oncology Holdings director and chief executive officer Jason Lettmann reported an open-market sale of 12,311 shares of common stock at $2.17 per share on March 19, 2026. According to the filing, the shares were sold to satisfy his tax obligations related to the vesting of performance-based restricted stock units. After this transaction, he directly holds 293,609 shares of ALX Oncology common stock.
ALX Oncology Holdings Inc. senior vice president of finance and chief accounting officer Shelly Pinto reported a small open-market sale of common stock. On March 19, 2026, she sold 903 shares at $2.17 per share. According to the footnote, the shares were sold to satisfy her tax obligations related to the vesting of performance-based restricted stock units, indicating a tax-driven, routine transaction rather than a discretionary portfolio move. After this sale, Pinto directly holds 86,805 shares of ALX Oncology common stock.
ALX Oncology Holdings Inc reported that Chief Medical Officer Barbara Klencke received a grant of stock options representing 700,000 shares of the company’s stock. This is recorded as a derivative security transaction categorized as a grant, award, or other acquisition.
According to the vesting terms, one-fourth of the shares subject to the option vest on February 25, 2027, and the remaining portion vests in equal monthly installments of 1/48th thereafter. Following this grant, she is shown as holding 700,000 stock options directly.
ALX Oncology Holdings Inc. senior vice president and chief accounting officer Shelly Pinto reported an open-market sale of 565 shares of common stock at $2.27 per share. According to the disclosure, the shares were sold solely to cover tax obligations from vesting restricted stock units. After this transaction, Pinto holds 87,708 shares directly.
ALX Oncology Holdings CEO Jason Lettmann reported a routine tax-related share withholding. On the RSU vesting date, 2,201 shares of common stock were withheld at $2.27 per share to cover his tax liability, a non‑market disposition. Following this, he directly owns 305,920 shares, which include 3,000 shares acquired under the company’s employee stock purchase plan on December 31, 2025.
ALX Oncology director and 10% owner Corey S. Goodman, through entities associated with venBio, reported a large indirect purchase of the company’s common stock. On February 2, 2026, venBio Global Strategic Fund II, L.P. acquired 3,184,713 ALX Oncology shares at $1.57 per share, bringing its indirectly reported holdings to 8,453,038 shares. Additional indirect holdings reported for entities linked to Goodman include 3,969,789 shares held by venBio Global Strategic Fund, L.P., 461,811 shares held by venBio SPV, LLC, 113,287 shares held by the Goodman Barinaga Trust, and 54,083 shares held by Emaldi Corporation. Goodman serves in oversight roles at these entities and disclaims beneficial ownership of the securities, except to the extent of his indirect pecuniary interest.
ALX Oncology Holdings Inc. reported that its Chief Financial Officer, Shantharam Harish, received a grant of stock options on January 26, 2026. The award covers 303,000 stock options with an exercise price of $1.48 per share, giving the right to buy common stock.
The options vest in 48 equal monthly installments starting on February 26, 2026, and are scheduled to expire on January 25, 2036. Following this grant, Harish beneficially owns 303,000 derivative securities directly in the form of these stock options.
ALX Oncology Holdings Inc. officer Shelly Pinto was granted 192,000 stock options on January 26, 2026. These options have an exercise price of $1.48 per share and were awarded at a cost of $0.00 to Pinto.
The options relate to ALX Oncology common stock and are held directly. They become exercisable over time, vesting in 48 equal monthly installments beginning on February 26, 2026, and are scheduled to expire on January 25, 2036 if not exercised.
ALX Oncology Holdings Inc. granted its Chief Executive Officer and director Jason Lettmann a significant stock option award. On January 26, 2026, he received an option to purchase 912,000 shares of common stock at an exercise price of $1.48 per share, expiring January 25, 2036.
The option vests in 48 equal monthly installments beginning February 26, 2026, meaning the award vests gradually over four years as long as service conditions are met. Following this grant, Lettmann beneficially owns 912,000 derivative securities directly in the form of these stock options.
ALX Oncology Holdings Inc. reported an insider equity award to director and 10% owner Corey S. Goodman. On January 20, 2026, Goodman received a stock option covering 40,400 shares of common stock with an exercise price of $1.32 per share, expiring on January 19, 2036.
The option vests in 12 equal monthly installments beginning on February 20, 2026, meaning the award becomes fully vested over one year. Following this transaction, Goodman beneficially owned 40,400 derivative securities directly in the form of this stock option.
ALX Oncology Holdings Inc. director receives new stock option grant. Director Garland J. Scott was awarded a stock option covering 40,400 shares of ALX Oncology common stock on January 20, 2026. The option has an exercise price of $1.32 per share and was granted at no purchase price for the option itself. Following this award, Scott beneficially owns 40,400 derivative securities directly.
The option vests in 12 equal monthly installments beginning on February 20, 2026, providing gradual ownership over one year, and is scheduled to expire on January 19, 2036 if not exercised.
ALX Oncology Holdings Inc. director Alan B. Sandler reported a new stock option grant for 10,100 shares of common stock. The option has an exercise price of $1.32 per share and was awarded on January 20, 2026. According to the filing, these option shares vest in 12 equal monthly installments beginning on February 20, 2026, spreading vesting over one year. The option expires on January 19, 2036, and Sandler is shown as directly holding 10,100 derivative securities following this transaction, reflecting this newly granted award.
ALX Oncology Holdings Inc. director Daniel J. Curran reported a new stock option grant in a Form 4 filing. On January 20, 2026, he was awarded a stock option (right to buy) covering 16,833 shares of common stock at an exercise price of $1.32 per share. The option vests in 12 equal monthly installments beginning on February 20, 2026, providing steady monthly vesting over one year. The option expires on January 19, 2036, giving a long-term window to exercise. Following this grant, Curran beneficially owns 16,833 derivative securities directly.
ALX Oncology Holdings director Chris H. Takimoto received a grant of stock options on January 20, 2026. The award covers 40,400 stock options with an exercise price of $1.32 per share, giving the right to buy the company’s common stock at that price in the future. The options expire on January 19, 2036, providing a long-term incentive tied to the company’s share performance.
According to the filing, the 40,400 options vest in 12 equal monthly installments beginning on February 20, 2026. After this grant, Takimoto beneficially owns 40,400 derivative securities directly.
ALX Oncology Holdings Inc. director Rekha Hemrajani received a new stock option grant. On January 20, 2026, she was awarded options to purchase 40,400 shares of ALX Oncology common stock at an exercise price of $1.32 per share. These options were granted at no upfront cost and are held directly.
The options are scheduled to vest in 12 equal monthly installments, beginning on February 20, 2026, and will remain exercisable until January 19, 2036, if service and other applicable conditions are met. After this grant, Hemrajani beneficially owns 40,400 stock options for ALX Oncology common shares.
ALX Oncology Holdings Inc. reported an insider stock sale by Shelly Pinto, the company’s SVP, Finance and CAO. On 01/06/2026, Pinto sold 3,925 shares of common stock at a weighted average price of $1.11 per share, in multiple trades between $1.11 and $1.12.
According to the filing, the sale was made to cover the reporting person’s tax obligations related to the vesting of restricted stock units. After this transaction, Pinto beneficially owned 88,273 shares of ALX Oncology common stock, which includes 3,000 shares acquired under the company’s employee stock purchase plan on December 31, 2025.
ALX Oncology Holdings Inc. (ALXO) reported an insider equity grant. The company’s Chief Executive Officer and Director received an employee stock option for 597,500 shares at an exercise price of $1.70 on October 14, 2025, expiring on October 14, 2035.
Vesting is staged: one‑third vests on April 30, 2026 and the remaining two‑thirds on October 31, 2026. Following the grant, 597,500 derivative securities were beneficially owned, held directly.
ALX Oncology Holdings (ALXO) reported an insider equity award for its Chief Financial Officer on a Form 4. The filing shows a grant of 198,750 employee stock options on 10/14/2025 with an exercise price of $1.7 per share and an expiration date of 10/14/2035. The grant was recorded at a price of $0 for the derivative security, indicating an award rather than a purchase.
The vesting schedule splits the award into two tranches: one-third vests on April 30, 2026, and the remaining two-thirds vest on October 31, 2026. Following the transaction, the filing lists 198,750 derivative securities beneficially owned, held directly.
ALX Oncology (ALXO) reported an insider equity award. On October 14, 2025, the company granted its SVP, Finance and CAO an employee stock option for 140,000 shares of common stock at a $1.70 exercise price, recorded as a grant at $0 price and held directly.
The option vests in two steps: one‑third on April 30, 2026 and the remaining two‑thirds on October 31, 2026. Following the transaction, 140,000 derivative securities were beneficially owned.